DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the SUN PHARMA ADV.RES.CO.LTD (SPARC) share price today?

SUN PHARMA ADV.RES.CO.LTD (SPARC) is trading at ₹235.2 on the NSE, down 6.09% on the day. Source: DocStoX.

What is the PE ratio of SUN PHARMA ADV.RES.CO.LTD?

SUN PHARMA ADV.RES.CO.LTD has a price-to-earnings (PE) ratio of 5.8 in the Healthcare sector.

What is the market capitalisation of SUN PHARMA ADV.RES.CO.LTD?

SUN PHARMA ADV.RES.CO.LTD has a market capitalisation of approximately ₹7,632 crore.

SUN PHARMA ADV.RES.CO.LTD

SPARC·NSE·Healthcare

₹235.20▼ -15.25 (-6.09%)

Healthcare · Pharmaceuticals

High-quality returns — 158% on equity

Day₹228.15

₹250.49

52W₹108

₹28970%

Open

₹250.49

High

₹250.49

Low

₹228.15

Prev Close

₹250.45

Volume

27.79L

VWAP

₹236.33

Snapshot

Key fundamentals

Market Cap

₹7,632 Cr

P/E Ratio

5.80Cheap

P/B Ratio

6.72

EPS

₹40.55

Book Value

₹41.26

ROE

157.88%Strong

ROCE

-298.00%Weak

Dividend Yield

0.00%

Debt / Equity

0.42Moderate

Face Value

₹1.00

52W High

₹289.00

52W Low

₹108.00

Sector

Healthcare

Industry

Pharmaceuticals

Fairly Valued

None moatHigh uncertainty

Fair value estimate

₹194

▼ 17.5%downside

Trading at ₹235 — 18% above our estimate

BearFair valueBull

₹165₹194₹223

/100

Business quality — Watch the fundamentals

Growth 0Profitability 50Efficiency 0Valuation 90

Plain English

Our view

High-quality returns — 158% on equity
Low debt relative to equity
Revenue has been shrinking

Strengths

Low debt relative to equity
Strong returns on equity (158%)
Reasonably priced at 6× earnings
Promoters hold a controlling stake

Risks

Revenue has been shrinking
Fundamental red flags (Piotroski 2/9)

How we got there

Fair value methods

Residual income

Needs a return-on-equity figure

—

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹194

Analyst target

No analyst coverage

—

Blended fair value₹194

What the numbers say

Investment thesis

Bull case

Low debt relative to equity
Strong returns on equity (158%)
Reasonably priced at 6× earnings
Promoters hold a controlling stake

Bear case

Revenue has been shrinking
Fundamental red flags (Piotroski 2/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

5.8Cheap

Below 15× is value territory; above 35× prices in strong growth

ROE

157.9%Strong

Above 15% is considered healthy for Indian equities

ROCE

-298.0%Weak

Above 18% means capital is working hard

Debt/Eq

0.42Moderate

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹7,632 Cr

P/B

6.72

EPS

₹40.55

Div Yield

—

What changed

Recent changes

No notable changes to report.

What matters

News impact

Overview

Valuation

Attractive

P/E 5.8×

Growth

Strong

+99% rev CAGR

Profitability

Excellent

157.9% ROE

Financial health

Comfortable

D/E 0.42

Momentum

N/A

No technicals

Today

Trading activity

Delivery %32.8%

Turnover₹6568.59L Cr

Trades47,749

VWAP₹236.33

Face value₹1.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+98.8%

+49.3%

10Y

+27.9%

Profit

—

10Y

—

EPS

—

10Y

—

Profile

Pros

Company has delivered good profit growth of 65.3% CAGR over last 5 years

Watch-outs

Cons

Stock is trading at 6.44 times its book value
Working capital days have increased from -770 days to 214 days

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 May 2026

Ownership was broadly stable versus the previous quarter. The QoQ column shows each group's change versus the prior quarter.

66%

Promoter

Promoters

65.7%0.00

Public

19.1%-12.63

FII / FPI

2.5%-0.01

DII

0.1%+0.01

Others

12.6%

Total shareholders

1,37,538

Quarterly trend

Ownership over time

Q1 FY27

Promoter65.67%

FII2.47%

DII0.10%

Public19.13%

Others12.63%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Sun Pharma Advanced Research Company Ltd is engaged in the business of research and development (R&D) of pharmaceutical products.[1]